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Lidocaine bears in its structure both an aromatic ring and a terminal amine, which can be
protonated at physiological pH, linked by an amide group. Since lidocaine causesmultiple
inhibitory actions on nicotinic acetylcholine receptors (nAChRs), this work was aimed to
determine the inhibitory effects of diethylamine (DEA), a small molecule resembling the
hydrophilic moiety of lidocaine, on Torpedo marmorata nAChRs microtransplanted to
Xenopus oocytes. Similarly to lidocaine, DEA reversibly blocked acetylcholine-elicited
currents (IACh) in a dose-dependent manner (IC50 close to 70µM), but unlike lidocaine,
DEA did not affect IACh desensitization. IACh inhibition by DEA was more pronounced at
negative potentials, suggesting an open-channel blockade of nAChRs, although roughly
30% inhibition persisted at positive potentials, indicating additional binding sites outside
the pore. DEA block of nAChRs in the resting state (closed channel) was confirmed by
the enhanced IACh inhibition when pre-applying DEA before its co-application with ACh,
as compared with solely DEA and ACh co-application. Virtual docking assays provide a
plausible explanation to the experimental observations in terms of the involvement of
different sets of drug binding sites. So, at the nAChR transmembrane (TM) domain,
DEA and lidocaine shared binding sites within the channel pore, giving support to
their open-channel blockade; besides, lidocaine, but not DEA, interacted with residues
at cavities among the M1, M2, M3, and M4 segments of each subunit and also at
intersubunit crevices. At the extracellular (EC) domain, DEA and lidocaine binding sites
were broadly distributed, which aids to explain the closed channel blockade observed.
Interestingly, some DEA clusters were located at the α-γ interphase of the EC domain, in
a cavity near the orthosteric binding site pocket; by contrast, lidocaine contacted with all
α-subunit loops conforming the ACh binding site, both in α-γ and α-δ and interphases,
likely because of its larger size. Together, these results indicate that DEA mimics some,
but not all, inhibitory actions of lidocaine on nAChRs and that even this small polar
molecule acts by different mechanisms on this receptor. The presented results contribute
to a better understanding of the structural determinants of nAChR modulation.
Keywords: diethylamine, lidocaine, nicotinic acetylcholine receptors, Xenopus oocytes, microtransplanted
receptors, allosteric modulation
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INTRODUCTION
Nicotinic acetylcholine receptors (nAChRs) belong to the “Cys-
loop” superfamily of ligand-gated ion channels (LGICs). All
members of this family of receptors are constituted by five
subunits, each one contributing four transmembrane spanning-
segments (M1–M4), which conform a channel pore lined by
the M2 segment of each subunit (Albuquerque et al., 2009;
Hurst et al., 2013). nAChRs are widely distributed in central
and peripheral nervous systems, but they are also expressed in
skeletal muscle fibers and other tissues where they play relevant
functional roles (Gotti and Clementi, 2004). Although there is
a large heterogeneity in the structure and function of nAChRs
from different cells, all of them behave as allosteric proteins,
undergoing conformational changes (from resting to active or
desensitized states) when specific ligands bind to their orthosteric
sites (Taly et al., 2009; Cecchini and Changeux, 2015).
nAChRs are involved in the etiopathology of several
neurological disorders, including Parkinson’s disease, some
myasthenic syndromes, addiction, depression, cognitive deficits
(including Alzheimer’s disease), some types of epilepsy and also
seem to contribute to modulate pain or inflammatory responses
(Gotti and Clementi, 2004; Dani and Bertrand, 2007; Hurst
et al., 2013). Hence, it is important to study the mechanisms of
modulation of these receptors by allosteric ligands and to unravel
their specific binding sites, in order to develop new therapeutic
agents (Arias, 2010; Chatzidaki and Millar, 2015).
Lidocaine is commonly used in clinical practice as a local
anesthetic and as an anti-arrhythmic agent because it reversibly
blocks voltage-dependent Na+ channels (Hille, 1966). Besides,
lidocaine modulates the function of other voltage-dependent
channels, including Ca2+ (Xiong and Strichartz, 1998) and
K+ channels (Trellakis et al., 2006) and different pentameric
LGICs, such as 5-hydroxytryptamine-3 (Ueta et al., 2007), glycine
(Gly) and GABAA receptors (Hara and Sata, 2007), nAChRs
(Steinbach, 1968; Gentry and Lukas, 2001; Alberola-Die et al.,
2011, 2013) and the prokaryotic channels GLIC and ELIC (Hilf
et al., 2010; Gonzalez-Gutierrez and Grosman, 2015). However,
the specific mechanisms of action of lidocaine on neuroreceptors
are not fully understood.
Recently, we have described that lidocaine blocks muscle-type
(Alberola-Die et al., 2011) and neuronal heteromeric (Alberola-
Die et al., 2013) nAChRs by multiple mechanisms that can
be dissected, at least partially, by dose. At doses lower than
the IC50, lidocaine inhibits nAChRs mainly by open-channel
blockade, whereas at higher concentrations (equal or higher than
the IC50) it also causes closed-channel blockade and enhances
desensitization. Now, our aim is to unravel the structural
determinants within the lidocaine molecule responsible for
Abbreviations: ACh, acetylcholine; ANR, normal Ringer solution with atropine;
DEA, diethylamine; EC domain, extracellular domain; ELIC, Erwinia chrysanthemi
ligand-gated ion channel; GABAAR, gamma-aminobutyric acid type A receptors;
GLIC, Gloebacter violaceus ligand-gated ion channel; GlyR, glycine receptor; IACh,
ACh-elicited current; LA, local anesthetic; LGIC, ligand gated ion channel; MS-
222, ethyl 3-aminobenzoate methanesulfonate; n, number of oocytes; N, number
of oocyte donors; nAChR, nicotinic acetylcholine receptor; NR, normal Ringer
solution; TM, transmembrane segment.
specific effects on muscle-type nAChRs. So, in this work we have
analyzed the effects of diethylamine (DEA), a small molecule
resembling the hydrophilic moiety of the lidocaine molecule (see
Figure 1A), on nAChRs.
When dealing with ligands bearing different chemical groups
in their structure and exhibiting multiple functional effects, it
would be ideal to be able to dissect the functional role of
individual structural components by using smaller molecules
mimicking specific domains of the larger ligand. This is the
rationale behind this study on the hydrophilic DEA, which
mimics the terminal amine group of lidocaine and indeed
reproduces with high fidelity some, but not all, of its effects. Once
this has been stablished, it opens the way to use small molecules
resembling the hydrophobic moiety of lidocaine to determine
which, if any, of the effects of the entire ligand onAChRs function
can also be attributed to such hydrophobic domain.
Preliminary results have been published elsewhere (Alberola-
Die et al., 2012).
MATERIALS AND METHODS
Purification and Reconstitution of nAChRs
nAChRs from Torpedo marmorata electroplax were purified
by bromoacetylcholine-affinity chromatography in the presence
of asolectin lipids using cholate as a detergent. After elution
with carbamylcholine, purified receptors were dialyzed and
reconstituted in asolectin lipids at a final protein concentration
of 0.3–1.2mg ml−1. Samples were aliquoted and stored in liquid
nitrogen (Ivorra et al., 2002).
Oocyte Preparation and Microinjection
Adult female Xenopus laevis (purchased from Harlan Interfauna
Ibérica S.L., Barcelona, Spain; and Centre National de la
Recherche Scientifique, Montpellier, France) were immersed in
cold 0.17% MS-222 for 20min and a piece of ovary was drawn
out aseptically. Animal handling was carried out in accordance
with the guidelines for the care and use of experimental animals
adopted by the E.U. and the animal protocol was approved by
the ethic committee of Universidad de Alicante. Stage V and
VI oocytes were isolated and their surrounding layers removed
manually. Cells were kept at 15–16◦C in a modified Barth’s
solution [88mM NaCl, 1mM KCl, 2.40mM NaHCO3, 0.33mM
Ca(NO3)2, 0.41mM CaCl2, 0.82mM MgSO4, 10mM HEPES
(pH 7.4), 100 U ml−1 penicillin, and 0.1mg ml−1 streptomycin]
until used. Oocytes were microinjected with 100 nl of an aliquot
of reconstituted nAChRs (Morales et al., 1995).
Two-Electrode Voltage-Clamp Recordings
in Oocytes
Membrane current recordings were performed at 21–25◦C, 16–
72 h after proteoliposome injection, using a high compliance
two-microelectrode voltage-clamp system (TurboTEC-10CD,
npi Tamm, Germany). The recording methodology has been
described previously (Morales et al., 1995; Olivera-Bravo et al.,
2005). Briefly, intracellular microelectrodes (0.8–3 M) were
filled either with 3M KCl or potassium acetate for voltage
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FIGURE 1 | DEA effects on ACh-induced currents (IAChs). (A) Molecular structures of protonated lidocaine and diethylamine (DEA), showing the resemblance of
DEA to the hydrophilic moiety of lidocaine. Note that DEA is positively charged at physiological pH, as most lidocaine molecules. (B) Superimposed IAChs recorded in
the same nAChR-bearing oocyte by successive applications of 10µM ACh either alone (Control, black) or together with DEA (orange) at the indicated concentrations.
In this and subsequent figures, unless otherwise stated, the holding potential was −60mV, downward deflections denote inward currents and the horizontal bar above
records corresponds to the timing of drug application. (C) DEA concentration-IACh inhibition relationship. Amplitude of the IAChs evoked in presence of DEA was
normalized to the IACh elicited by ACh alone (Control) and plotted vs. the logarithm of DEA concentration. Data are the average of four oocytes from different donors
and error bars, in this and following figures, are SEM; solid line is a sigmoid curve fitted to the data. (D) Superimposed IAChs recorded sequentially in the same oocyte
by superfusing the cell with 10µM ACh alone [(1), bar of solid circles and black recording], co-applied with DEA [100µM; (2), bar of open circles and orange recording]
or when changing from ACh plus DEA to ACh alone at the time indicated by the corresponding bar [(3), bar of open circles followed by solid circles and blue recording].
recording and current injection, respectively. Oocytes were
placed in a 150µl recording chamber and continuously
superfused with normal frog Ringer’s solution (NR: 115mM
NaCl, 2mM KCl, 1.8mM CaCl2, 5mM HEPES, pH 7.0)
supplemented with 0.5µM atropine sulfate (normal Ringer with
atropine, ANR) to block any muscarinic response (Kusano et al.,
1982). The membrane potential was held at −60mV, unless
otherwise stated. ACh and other tested drugs were diluted in
ANR solution and oocytes were superfused with them at a flow
rate of 13–17ml min−1. Membrane currents elicited by ACh
(IACh) either alone or co-applied withDEA, were low-pass filtered
at 30–1000Hz and, after sampling at fivefold the filter frequency
(Digidata 1200 Series and Digidata 1440A; Axon Instruments,
Foster City, CA, USA), recorded on two PC-computers, using
the WCP v.3.2.8 package developed by J. Dempster (Strathclyde
Electrophysiology Software, University of Strathclyde, Scotland,
UK) and AxoScope v. 10.0.0.60 (Molecular Devices Corporation,
Sunnyvale, U.S.A.).
Experimental Design
DEA concentration-IACh inhibition relationship was determined
by measuring IAChs evoked by 10µM ACh alone or together
with different DEA concentrations. For competition assays, ACh
concentration-IACh amplitude curves were obtained by exposing
injected oocytes to increasing ACh concentrations, either alone
or together with 100µMDEA. IAChs recorded in the presence or
absence of DEA were normalized to the IACh evoked by 1mM
ACh alone and fitted to a sigmoid curve. To allow nAChRs to
recover from desensitization, the interval between consecutive
ACh applications was at least 5min. To assess the blockade of
resting nAChRs by DEA, we compared the IAChs elicited by
ACh (from 1µM to 1mM) alone or co-applied with 100µM
DEA either directly or after pre-application of DEA (same
concentration) for 12 s.
When studying the voltage dependence of the IACh blockade
by DEA, series of 800ms voltage pulses (in 10mV steps
from −120 to −20mV, followed by 20mV jumps from −20
to+60mV; occasionally, in 20mV steps from−120 to+60mV)
were given to the oocyte before ligand superfusion and during the
IACh plateau elicited by 10µM ACh, either alone or co-applied
with DEA at different concentrations. In a few cells, the−120mV
pulse duration was extended up to 1500ms to allow a more
complete current relaxation.
Data Analysis and Statistical Procedures
Inhibition curves were determined by measuring IACh evoked by
10µM ACh in the presence of different DEA concentrations.
IAChs elicited in the presence of DEA were normalized to the
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IACh evoked by ACh alone. Data were fitted to a single-site
inhibition curve using the Origin 6.1 software (OriginLab Corp.
Northampton, MA, U.S.A.).
Reversibility of IACh blockade by DEA was determined by
giving 32 s pulses of ACh either alone or co-applied with DEA,
for solely the first 12 s or during the whole pulse; IACh recovery
was measured 20 s and 7min after DEA washout. The percentage
of recovery from blockade (% Recovery) was obtained using the
equation:
% Recovery =
[(
IACh after DEA − IACh+DEA)/(IACh − IACh+DEA
)]
× 100
(1)
where IACh is the current amplitude evoked by 10µMACh alone;
IACh+DEA, is the current elicited by co-application of 10µMACh
with 100µM DEA; and IACh after DEA is the current obtained 20 s
or 7min after DEA removal.
The rate of desensitization was determined by measuring the
IACh amplitude elicited by 100µM ACh, either alone or co-
applied with up to 200µM DEA, at different times after IACh
peak. Desensitization rates were obtained using the equation:
Dti = [1− (Iti/Ipeak)]× 100 (2)
where Dti is the desensitization value at the specified time; Ipeak
the IACh amplitude at the peak; and Iti the current amplitudes
remaining 2, 10, and 20 s after the peak (Olivera-Bravo et al.,
2007). The apparent time-to-peak was determined as the time
elapsed from IACh onset to the IACh peak. We have called
this parameter as “apparent” time-to-peak, just to indicate that
these values do not necessarily reflect “real” time-to-peak values
of nAChR activation but those observed in our experimental
conditions.
To characterize the pharmacological profile of DEA, nAChRs
were activated by different ACh concentrations either alone or
co-applied with DEA (at roughly its IC50), just directly or after
pre-application of DEA for 12 s. Dose-response data were fitted
to the following form of the Hill equation:
I/Imax =
[
1+
(
EC50/
[
ACh
])nH ]−1 (3)
where I is the IACh peak elicited at a given ACh concentration
(applied either alone or together with DEA); Imax is the
maximum IACh recorded; EC50 is the agonist concentration
required to obtain one-half the maximum IACh; and nH is the Hill
coefficient.
Net i/v curves for IACh were obtained subtracting, for each
voltage, the steady-state currents attained in ARN (measured
during the last 100ms of the pulse) from the corresponding
ones recorded in presence of ACh. These net IACh values were
normalized, for each oocyte, to the ACh response at−60mV. The
percentage of IACh inhibition at different membrane potentials
(Vm) was computed using the following equation:
InVm = [1− (I(ACh+DEA) at Vm/I(ACh) at Vm )]× 100 (4)
where InVm is the percentage of IACh inhibition at the
corresponding Vm; I(ACh+DEA) at Vm is the IACh amplitude in
the presence of ACh and DEA at Vm; and I(ACh) at Vm is
the IACh elicited by ACh alone at Vm. Values from the i/v
relationship obtained at different blocker concentrations were
fitted to Equations (5) and (6) to estimate the fraction of voltage
field (δ) sensed by DEA at its binding site inside the channel.
The apparent Ki for each membrane potential, which is the
concentration of DEA that reduces IACh amplitude to the half,
was estimated from the following equation:
IACh+DEA/IACh = Imin + [(Imax − Imin)/(1+ ([DEA]/Ki)
n)]
(5)
where IACh+DEA is the current evoked by co-application of
10µM ACh with a given concentration of DEA; IACh is the
current elicited by 10µM ACh alone (control conditions); Imin
and Imax are, respectively, the minimum and maximal fractional-
current amplitudes evoked; [DEA] is the DEA concentration; and
n is the slope factor. To estimate the fraction of the voltage field
experienced by the blocking particle (δ), we used the following
form of the Woodhull equation (Woodhull, 1973):
logKi (V) = logKi (0mV)+(zδFV/2.303RT) (6)
where Ki (V) is estimated from Equation (5) at each membrane
potential; Ki (0 mV) is the Ki-value at 0mV; z is the electric
charge of DEA and R, T, and F have the usual thermodynamic
meanings.
Unless otherwise specified, values given are the mean± SEM;
“n” indicates the number of oocytes and “N” is the number
of donors from which data were obtained. When comparing
two-group means of normally distributed values, the Student’s
t-test was used; otherwise, Mann-Whitney rank-sum test was
applied. Among-group differences for non-normally distributed
data were determined by the Kruskal–Wallis analysis of variance
on ranks and multiple comparisons vs. a control group were
carried out with the Dunn’s method. A significance level of p <
0.05 was considered for all cases.
Virtual Docking Assays
The structure of the full domains of Torpedo nAChR was
taken from RCSB Protein Data Bank (code 2BG9), which was
determined, in the closed channel state, by electron microscopy
at 4 Å resolution (Unwin, 2005). The edition of the protein
was made using DeepView v4.1 (Guex and Peitsch, 1997) and
Yasara (Krieger et al., 2002, 2004) software without further
optimization. Lidocaine and DEA structures (CID 8021 and
3676, respectively) were taken from NCBI Pubchem database
(http://www.ncbi.nlm.nih.gov/pccompound). A global docking
procedure was accomplished with AutoDock 4 (Morris et al.,
2008) implemented in Yasara, where a total of 500–1000 flexible
docking runs were set and clustered around the putative binding
sites. The program then performed a simulated annealing
minimization of the complexes, which moved the structure to
a nearby stable energy minimum, by using the implemented
AMBER 99 force field (Duan et al., 2003). The binding energy was
obtained by calculating the energy at infinite distance between
the ligand and the nAChR oligomer and subtracting the energy
of the whole complex. The more positive the binding energy, the
more favorable was the interaction in the context of the force
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field. The best binding energy complex in each cluster was stored,
analyzed and used to select the best orientation of the interacting
partners. Figures were drawn with open source Pymol (The
PyMOL Molecular Graphics System, Version 1.8 Schrödinger,
LLC, at http://www.pymol.org/). Yasara pH command was set to
7, ensuring that molecules preserve their pH dependency of bond
orders and protonation patterns. In this way, almost all DEA
molecules remained charged during the docking procedure, but
only 86% of the lidocaine molecules.
Drugs
ACh, atropine sulfate, DEA, MS-222, penicillin, and
streptomycin were from Sigma (St. Louis, MO, USA). HEPES
was obtained from Acros Organics (New Jersey, NJ, USA).
Reagents of general use were purchased from Scharlau Chemie
SA (Barcelona, Spain). All solutions were made in ANR just
before each application, unless otherwise stated.
RESULTS
Inhibition of IACh by DEA
In either uninjected cells or oocytes bearing nAChRs, with the
membrane potential held at −60mV, DEA superfusion did not
modify their membrane conductance, even at concentrations
as high as 10mM (not shown). However, in oocytes bearing
nAChRs, co-application of 10µM ACh with 0.1µM–10mM
DEA reversibly inhibited IAChs in a concentration-dependent
manner (Figure 1B). The percentage of IACh, normalized to the
control value obtained in presence of 10µM ACh alone, was
plotted vs. the logarithm of DEA concentration, and values were
fitted to a sigmoid curve (Figure 1C). The half inhibitory DEA
concentration (IC50) was 68µM (range 60–102µM), similar to
that found for lidocaine (73µM, range 62–83µM; Alberola-
Die et al., 2011), and the Hill coefficient (nH) was 1.15 ± 0.04,
suggesting that a single DEA molecule caused lidocaine-like
nAChR blockade.
IACh recovery after DEA (100µM) superfusion was slow and
IACh did not reach control values even 7min after DEA washout.
So, the percentage of IACh recovery, estimated from Equation (1),
was 73 ± 8% (n = 7, N = 6; Figure 1D) and 86 ± 2% (n = 16,
N = 11; not shown) at 20 s and 7min, respectively, indicating
that a fraction of DEA molecules remains bound to the nAChR
several minutes after DEA rinsing out.
DEA has No Effect on IACh Desensitization
and the Apparent Time-To-Peak
The IACh decay was not affected in oocytes superfused with
100µM ACh together with DEA at the IC50 (70µM). As shown
in Figures 2A,B, DEA did not change IACh desensitization even
when DEA concentration was increased to 200µM, roughly
threefold its IC50. The Dti-values obtained at 2 and 20 s (see
Equation 2 in Materials and Methods) were: 30 ± 2% and 89 ±
1% (n = 18, N = 7) for IAChs elicited by ACh alone vs. 29 ±
4% and 89 ± 2% (the same cells) when ACh was co-applied
with 200µM DEA (Figure 2B; p > 0.05, Mann-Whitney rank-
sum test). Moreover, DEA at concentrations as high as 200µM
had no effect on the time elapsed from IACh onset to the IACh
FIGURE 2 | DEA neither affects IACh desensitization nor apparent
time-to-peak. (A) Superimposed IAChs elicited by application of 100µM ACh
either alone (Control, black recoding) or together with DEA (+200µM DEA,
orange recording), and by re-applying 100µM ACh alone 7min after DEA
washout (Postcontrol, gray recording). Note that IACh amplitudes have been
scaled to the same size to better showing IACh desensitization. (B) Plots
showing the percentage of IACh desensitization at different times (2, 10, and
20 s) after the IACh peak. Data were computed from recordings as shown in
(A), by applying 100µM ACh either alone (Control, filled circles and continuous
black line; Postcontrol, filled triangles and dashed line) or plus 200µM DEA
(orange circles and line). (C) Column graph of the IACh apparent time-to-peak
when applying 100µM ACh alone (Control and Postcontrol) or with DEA
(+200µM DEA). The number of oocytes (n) and donors (N) given in each
column is common to (B,C).
peak (the apparent time-to-peak was 2.1± 0.2 s for 100µMACh
alone against 1.9± 0.2 s for 100µMACh plus 200µMDEA; data
are from the same cells in which desensitization was measured;
p > 0.05, Mann-Whitney rank-sum test; Figures 2A,C). DEA
lack of effect on IACh desensitization and apparent time-to-peak is
in sharp contrast with the action of the entire lidocaine molecule
on nAChRs (Alberola-Die et al., 2011, 2013).
Voltage-Dependence of nAChR Blockade
by DEA
To assess whether IACh inhibition by DEA is voltage-dependent,
voltage pulses were applied to oocytes while superfusing the cell
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FIGURE 3 | Voltage-dependent blockade of IACh by DEA. (A) IAchs
(upper traces) recorded in an oocyte when applying the voltage protocol
shown on bottom, during the current plateau elicited by 10µM ACh either
alone (Control, black) or together with DEA (+100µM DEA, orange). (B) Net i/v
relationships for IACh evoked by ACh alone (10µM ACh, black filled circles and
line) or co-applied with 100µM DEA (+100µM DEA, orange open circles and
line), obtained when applying the voltage protocol shown in (A). Normalized
values represent the percentage of each IACh referred to its control at −60mV
and each point is the average of eight cells (N = 5). (C) Plot showing the
fraction of the IACh left by 100µM DEA (IACh+DEA), normalized to its control
(IACh), vs. the membrane potential. Note the linear voltage dependence of IACh
blockade by DEA in the range between −70 and −20mV; the discontinuous
red line shows the best linear fit to these points and the continuous line
indicates the fraction of IACh remaining at positive potentials in presence of
DEA. Inset shows the maximum longitudinal and transversal dimensions of the
DEA molecule.
with just ANR or during the IACh plateau elicited by 10µM
ACh either alone or co-applied with 100µM DEA (Figure 3A;
see Experimental Design in Materials and Methods). Figure 3B
shows the i/v relationship obtained when plotting the net IAChs
elicited by ACh, either alone or with DEA, normalized to its
control IACh at −60mV, against the membrane potentials tested.
The i/v curve for 10µM ACh alone showed a reversal potential
close to 0mV and the characteristic inward rectification of
IACh (Figure 3B, Morales et al., 1995). When DEA was co-
applied with ACh the IACh reversal potential was unmodified,
indicating that the channel selectivity was unaffected. However,
in the presence of DEA, IACh amplitude decreased in a voltage-
dependent way, the blockade being higher at negative potentials
(Figure 3B). Nevertheless, the voltage dependency was only
linear in the range from−70 to−20mV, since at potentials more
negative than −70mV the IACh blockade did not increase, but
even decreased. So, as displayed in Figure 3C, the fraction of
IACh remaining in the presence of DEA rose as the membrane
was hyperpolarized beyond −70mV. This biphasic behavior of
the voltage-dependent blockade of IACh by DEA at negative
potentials was not observed for lidocaine (Alberola-Die et al.,
2011), and could be due to the small size of DEA (see inset
Figure 3C). Interestingly, at positive potentials DEA blocked
roughly 30% of IACh (Figure 3C), indicating that DEA also causes
a significant voltage-independent blockade of nAChRs.
Since DEA caused a voltage-dependent blockade of nAChRs,
more evident between −70 and −20mV (Figures 3B,C), we
used in one cell the Woodhull’s equation (see Equations 4–6 in
Materials and Methods), restricted to this range of potentials, to
estimate the δ-value, which indicates the fraction of the voltage
field sensed by DEA at its binding site. The calculated δ-value
was 0.30 (assuming that z = 1), indicating that DEA binds to
the external third of the channel length.
Effects of DEA on nAChR Pharmacological
Profile
To study the effects of DEA on the ACh dose-IACh relationship,
ACh was applied in the same oocyte at increasing concentrations
(1µM–1mM) either alone or with 100µM DEA (Figure 4A).
Figure 4B shows the ACh dose-IACh curves obtained either in
absence or in presence of 100µM DEA, normalizing IACh values
to those evoked by 1mM ACh alone; data were fitted to sigmoid
curves with the Hill equation (see Equation 3 in Materials and
Methods). The EC50 for the control curve (ACh alone) was
46µM (range 16–59µM) and the nH 1.8 ± 0.1 (n = 4, N = 3),
values which are in good agreement with previous data (Morales
et al., 1995; Olivera-Bravo et al., 2005). In presence of 100µM
DEA, the maximum IACh amplitude decreased, suggesting a
non-competitive blockade (Figures 4A,B); besides, the dose-
response curve shifted to the right, increasing the EC50 more
than twice the original value (112µM, range 88–145µM) and
slightly decreasing the nH to 1.6 ± 0.1 (Figure 4B). As shown in
Figures 4A, 5C, co-application of 10µMACh with 100µMDEA
caused an IACh inhibition of 73± 1% (n = 29,N = 10), but when
the same concentration of DEA was co-applied with 1mM ACh,
the percentage of blockade was only 35 ± 7% (n = 5, N = 4;
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p < 0.05, t-test). Thus, the percentage of IACh inhibition by DEA
markedly depended on the ACh concentration, suggesting that
the blocking effect of DEA on nAChRs was not merely non-
competitive. This apparently competitive inhibition of IACh by
DEA could be explained, at least partially, by its binding to resting
nAChRs. To test this hypothesis, we determined the percentages
of IACh blockade induced by DEA (100µM) when it was pre-
applied to the cell for 12 s before being co-applied with ACh at
increasing concentrations (1µM–1mM; Figure 5A). Figure 5B
shows the ACh dose-IACh curves elicited by ACh either alone or
when it was co-applied with100µMDEA after its pre-application
for 12 s. In these experiments, the EC50 for ACh alone was 37µM
(range 14–115µM) and the nH 1.9 ± 0.1 (n = 7–11, N = 1–3)
whereas in presence of DEA the EC50 slightly increased, to 60µM
(range 52–126µM), and the nH was 1.6 ± 0.1. Noticeably, when
DEAwas pre- and co-applied with ACh, a smaller maximum IACh
amplitude was reached (Figures 5A,B) and the percentage of IACh
inhibition caused was similar for any ACh concentration above
10µM (p > 0.05, Kruskal Wallis ANOVA on ranks; red plot of
Figure 5C), indicating a non-competitive blockade of nAChRs.
Thus, the effect of DEA pre- and co-application strikingly
contrasted with that obtained by just DEA co-application with
ACh, since the latter showed an apparent competitive mode of
action while the former did not (Figures 4B, 5C). If DEA binds
to, and blocks, closed (resting) nAChRs, it would be expected that
DEA pre-application enhanced the IACh inhibition caused by just
DEA and ACh co-application, preferentially at the highest ACh
doses (1mM), as we have indeed observed (Figure 5C). This is
likely due to the fast activation of most nAChRs by 1mM ACh,
which prevented the effect of DEA on resting nAChRs when
ACh and DEA were just co-applied. On the other hand, at low
ACh doses only a small percentage of nAChRs were activated
by the agonist and consequently most nAChRs remained resting
and therefore susceptible to be blocked by DEA, acting as a
closed-channel blocker.
Virtual Docking Assays of DEA- and
Lidocaine-nAChR Interactions
Virtual docking assays were carried out to explore DEA- and
lidocaine-nAChR interactions using as template the full structure
of Torpedo nAChRs (see Materials and Methods). For these
assays 1000 runs of interactions were performed for DEA and 500
for lidocaine molecules.
The runs for DEA-nAChR interactions disclosed 30 clusters
of sites that differed in less than 5 Å of root-mean-square-
deviation of which 23 (77%) corresponded to EC, 2 (7%)
to TM, and the remaining 6 (16%) to intracellular domains;
this latter solutions have been discarded for further analysis
because DEA is impermeable through the cell membrane and
so they lack of functional meaning. As shown in Figure 6
(upper panels), the small and polar DEA barely binds to the
TM domain, except inside the channel pore (Figures 6A1,A2),
but it interacted quite well with different nAChR residues
located at the EC domain (Figures 6A1,A3). Regarding the EC
domain, most DEA-clusters were detected at αγ, β, or γ subunits
(Figures 6A1,A2). Interestingly, some DEA clusters were located
at the α-γ interphase, in a cavity near the orthosteric binding
FIGURE 4 | DEA effects on ACh concentration-IACh amplitude
relationship. (A) Recordings obtained by applying sequentially to the same
oocyte, at intervals of 5–30min, increasing ACh concentrations (3–1000µM)
either alone (black) or co-applied with 100µM DEA (orange). (B) Averaged
ACh concentration-IACh amplitude curves for IAChs elicited by ACh either
alone (black filled circles; n = 4, N = 3) or plus 100µM DEA (orange open
circles; same oocytes). Data were normalized to the maximal IACh elicited by
ACh alone and fitted to the Hill equation (continuous lines).
site (Figure 6A3). In fact, one of those clusters involved the
Y93 (loop A) of the α subunit and the D176 (loop F) of the
γ subunit, although due to the small size of DEA this cluster
did not reach neither the B nor the C-loop (Figure 6A3), which
also contribute with key residues to the ACh binding pocket
(Corringer et al., 2000). By contrast, the docking-assays did not
show any equivalent hotspot for DEA binding at the interphase
of α-δ subunits (see Figure 6A2). The remaining DEA clusters
at the EC domain were mostly at intersubunit crevices, although
a few solutions involved a single chain of α, β, or γ subunits
(Figures 6A1,A2). At the TM domain, we only detected 2 DEA
clusters located near and into the channel pore. Both clusters
involved interactions with α-β or α-δ subunits (Figure 6A2 and
Supplementary Figure 2) and their binding sites were at a depth
circa one third of the whole membrane thickness, from the
extracellular side (see Supplementary Figure 2).
Frontiers in Molecular Neuroscience | www.frontiersin.org 7 February 2016 | Volume 9 | Article 12
Alberola-Die et al. nAChR Blockade by Diethylamine
FIGURE 5 | DEA pre-application increases IACh inhibition and changes the pharmacological profile of nAChR inhibition. (A) IAChs elicited by
pre-application of 100µM DEA for 12 s followed by its co-application with ACh at the indicated concentrations (red recordings) or by just ACh at the same
concentrations (black recordings). (B) Averaged ACh concentration-IACh amplitude curves for IAChs evoked by ACh either alone (black filled circles; n = 4–8, N = 1–3)
or co-applied with 100µM DEA, after 12 s pre-application of DEA at the same concentration (red open circles; same oocytes). Data were normalized to the maximal
IACh elicited by ACh alone and fitted to the Hill equation (continuous lines). (C) Plot showing the percentage of IACh inhibition when ACh (at different concentrations)
was directly co-applied with 100µM DEA (orange circles; n = 5–29, N = 4–10), or when ACh and DEA co-applications were preceded by 100µM DEA
pre-application for 12 s (red circles; n = 7–11, N = 1–3). Asterisks indicate significant differences (p < 0.05, Kruskal Wallis ANOVA on ranks) respect to the IACh
blockade caused by solely co-applying 10µM ACh and 100µM DEA; the dashed line indicates 70% inhibition. Note that the percentage of IACh inhibition decreased
markedly when DEA was just co-applied with high ACh concentrations. By contrast, when DEA was pre-applied before its co-application with ACh, the percentage of
IACh blockade was similar at the different ACh concentrations (see text). The slight decrease in IACh blockade by DEA observed at 3µM ACh might not be reliable
because of the inaccuracies own to the small size of IACh at this agonist concentration.
For lidocaine-nAChR interactions, the docking assays
revealed multiple hotspots both at EC and TM domains
(Figure 6, lower panels), being remarkable the large number
of solutions found at the TM domain as compared with DEA.
At the EC region, it is noteworthy that one of the lidocaine
clusters fitted quite well at the nAChR ligand binding sites in
the α-γ (Figures 6B2,B3) and the α-δ interphases (Figure 6B2),
involving interactions with key residues of A, B, and C loops of
the α subunit. In contrast to DEA, the adjustment of this cluster
to the ACh-binding site is possible because the longitudinal and
transversal molecular dimensions of lidocaine (10.7 and 4.8–6.7
Å, respectively) are relatively close to those of the ACh molecule
(9.1 and 3.7 Å, respectively). Besides, some lidocaine clusters at
the EC domain were located at intersubunit crevices and, less
frequently, at intrasubunit sites, with a roughly similar pattern
to that found for DEA (compare Figure 6A1 and Figure 6B1).
At the TM domain, lidocaine clusters could be grouped in three
main types of interactions: (i) inside the pore of the channel,
where lidocaine contacted residues of M2 segments from four
or five subunits; (ii) intrasubunit interactions, with low binding
energy, at the cavities among the M1, M2, M3, and M4 segments
of each subunit; and (iii) intersubunit interactions, where α-γ,
α-δ, and β-δ hotspots presented the strongest interactions with
lidocaine.
DISCUSSION
Lidocaine is an aminoethylamide local anesthetic that in
physiological solutions exists as a mixture of charged and
uncharged species, due to its pKa of 7.8 (Liu et al., 2003).
Though it is believed that the charged form of lidocaine
mediates most of its therapeutic action (Narahashi et al.,
1969), the neutral form is also important because of its
higher ability to penetrate inside membranes. Interestingly,
both charged and uncharged forms of lidocaine seem to
contribute to the complex inhibitory action of this molecule on
muscle- (Alberola-Die et al., 2011) and neuronal-type (Alberola-
Die et al., 2013) nAChRs. Now, we report the effects of
DEA, a small amine mimicking the hydrophilic moiety of
lidocaine, on muscle-type nAChR, which is mostly protonated
at physiological pH, since it has a pKa of 10.49 (Sergeeva et al.,
2000).
Frontiers in Molecular Neuroscience | www.frontiersin.org 8 February 2016 | Volume 9 | Article 12
Alberola-Die et al. nAChR Blockade by Diethylamine
FIGURE 6 | Modeling of DEA and lidocaine binding to the EC and TM domains of the nAChR. (A1) Lateral view, in the membrane plane (top corresponding to
the synaptic cleft), of nAChR with bound DEA molecules. For this and following panels, the color code for nAChR subunit is: α (blue and cyan), β (magenta), γ (orange),
and δ (green). Ligand molecules are colored brown and represented in van der Waals spheres. Note that very few DEA-nAChR binding solutions (clusters) were
located at the TM domain, except two inside the channel pore (red circle), but there were several clusters distributed at the EC domain. (A2) Upper view, from the
synaptic cleft, of the nAChR with bound DEA. Note that at the EC domain DEA mainly interacts at intersubunit interphases, although some DEA clusters involved
single subunits. The red circle indicates the cluster sited within the channel pore. (A3) An expanded view of the EC domain at the α-γ interphase, corresponding to the
ACh-binding site (loops A, B, and C of the α subunit are indicated as reference). Note that one DEA cluster is near, but not inside, the pocket of the ACh-binding site
(see text for details). (B1) nAChR with lidocaine binding solutions is shown in a similar view as in (A1). Note that lidocaine clusters were more numerous at the TM
domain than those observed for DEA. Several TM clusters were located in intra- and intersubunit cavities and others inside the channel pore (red circle). At the EC
domain there were also several lidocaine clusters, with a distribution roughly similar to that found for DEA. (B2) Upper view, from the synaptic cleft, of the nAChR with
bound lidocaine. Note that both at the EC and TM domains lidocaine interacted at intra and intersubunit interphases and that several clusters were grouped inside the
channel pore (red circle). (B3) The same nAChR area as in (A3), showing a lidocaine cluster into the ACh-binding site.
DEA effects on nAChRs reported here showed important
analogies with those described for lidocaine. So, the IC50 for
DEA (68µM) was quite similar to that found for lidocaine
(73µM; Alberola-Die et al., 2011); besides, DEA and lidocaine
blocked nAChRs in a voltage-dependent manner, but also bound
to resting (closed) nAChRs. However, there were important
differences between lidocaine and DEA actions on nAChRs,
mainly in the desensitization rate, which was markedly increased
by lidocaine (Alberola-Die et al., 2011), but unaffected by DEA,
even at concentrations well over its IC50. This differential effect
is of great functional relevance because it points out that the
faster IACh decay induced by lidocaine is indeed caused by an
enhancement of nAChR desensitization, rather than by a slow
nAChR blockade.
It has been previously shown that DEA, and also
triethylamine, can directly activate muscle-type nAChRs,
and so act as partial agonists (Sánchez et al., 1986). However,
this effect was observed at concentrations far higher (mM range)
than those used here to characterize DEA inhibitory actions on
nAChRs. In our hands, such high doses would almost completely
block the IACh (Figure 1). Besides, in oocytes bearing nAChRs,
we could not detect any current activated by DEA alone,
even when applied up to 10mM. Thus, although it cannot be
fully ruled out that DEA causes some competitive inhibition on
nAChRs, themarked shift to the right of the ACh dose-IACh curve
(Figure 4) rather suggests the involvement of other mechanisms
(i.e., blockade of closed nAChRs, as indicated below). We have
also rule out that DEA caused an unspecific blockade of LGICs,
since 100µM DEA showed no effect on GABA-elicited currents
from rat neuronal GABAARs microtransplanted to Xenopus
oocytes (see Supplementary Figure 1), which belong to the same
family of LGICs. Nevertheless, it remains to be determined
whether or not DEA has specific effects or different potencies on
the neuronal nAChR subtypes.
DEA, as the entire lidocaine molecule, inhibited nAChRs
in a voltage-dependent manner, the blockade being higher at
negative potentials, which strongly suggests an open-channel
blockade caused by this positively-charged molecule. However,
at potentials more negative than −70mV, the IACh remaining
upon DEA did not decrease but rather increased (Figure 3C),
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in contrast to the voltage-dependent effect of lidocaine, which
kept increasing at very negative potentials (Alberola-Die et al.,
2011). This difference might arise because of the smaller size
of DEA, which could allow its permeation through the channel
pore, by a “punch-through” mechanism, as it has been proposed
for other small molecules in this receptor (Sine and Steinbach,
1984). In fact, from data on permeation of various sized cations,
the estimated size of the pore was 8.4 Å (Cohen et al., 1992),
which agrees well with the 9–10 Å pore diameter estimated from
images of the open state of Torpedo nAChRs (Unwin, 1995).
Given the small size of DEA (smaller than 7 Å in the long axis;
see Figure 3C) and its positive charge in physiological solutions,
this molecule could be electrostatically forced to move from its
binding site to the cytoplasm, releasing the nAChR from its
blockade at highly negative potentials. Virtual docking assays
also showed that both DEA and lidocaine might bind inside
the channel pore (Figure 6), though lidocaine protruding more
into it (Figure 6 and Supplementary Figure 2). The predicted
DEA binding sites within the pore were slightly shallower
than the lidocaine loci, in spite that for both molecules the
estimated δ-values were similar (about 30% of the electrical field).
Nevertheless, interpretation of the electrical distances (δ) is not
always straightforward because the IC50s are dependent not only
on the equilibrium dissociation constants of the blockers, but
also on the kinetics of the transitions between functional states
(Pascual and Karlin, 1998). Interestingly, whereas lidocaine could
interact within the pore at all five subunits, DEA interacted with
residues belonging to just two subunits (α-β or α-δ), which might
cause fainter interactions and thus facilitate the punch-through
occurrence.
IACh blockade by DEA could not be fully reversed by applying
pulses to positive potentials, which should unplug the positively
charged DEA from the channel pore. Thus, at +60mV, the
IACh inhibition caused by 100µM DEA (roughly 30%) was
voltage-independent (Figure 3C) and, so, it is not mediated by
open-channel blockade of nAChRs. Consequently, DEA should
also bind outside the pore and cause the blockade of resting
nAChRs, as it has been proposed for other non-competitive
blockers of nAChRs, including some cholinesterase inhibitors,
such as tacrine (Prince et al., 2002) or edrophonium (Olivera-
Bravo et al., 2007) and local anesthetics, such as tetracaine (Papke
and Oswald, 1989; Gallagher and Cohen, 1999; Middleton et al.,
1999) or lidocaine (Alberola-Die et al., 2011). DEA binding to
closed nAChRs is also supported by its pronounced inhibitory
action on nAChRs when it is pre-applied to the cells before
being co-applied with ACh (Figure 5). This was particularly
evident at high ACh doses (Figure 5C), since the fast opening
of nAChR channels by ACh prevented the DEA block of
resting receptors when DEA and ACh were solely co-applied.
As DEA caused nAChR blockade at positive potentials and it is
permanently charged (preventing their permeation through the
membrane), it is suggested that DEA blocked resting nAChRs by
its binding to extracellular residues outside the pore, which differs
from the binding of tetracaine within the channel on resting
nAChRs (Gallagher and Cohen, 1999; Middleton et al., 1999).
Accordingly, our virtual docking results showed that both DEA
and lidocaine bind at multiple loci on the EC domain, including
several sites at intersubunit interphases. Of particular functional
relevance seems the DEA binding to a cavity near the ligand-
binding pocket at the α-γ interphase (Figure 6A3). Interestingly,
this DEA binding site is very similar to that found for ketamine
binding to the homologous GLIC channel, as resolved by X-ray
crystallography at 2.99 Å (Pan et al., 2012; compare panels A1
and A2 of Supplementary Figure 2). It is also remarkable that
ketamine, a small water soluble amine, blocked GLIC channels
with an IC50 of 58µM, which is very close to that of DEA
for nAChRs blockade (Figure 1). Even more, ketamine also
blocked, at this range of concentrations, mammalian muscle-
and neuronal-type nAChRs by acting on the open and closed
states (Scheller et al., 1996), although it neither blocked GABAAR
nor GlyRs (Yamakura et al., 2000). Therefore, since DEA, and
most likely ketamine, binding site at the α-γ interphase of
nAChRs overlaps partially with the ACh-binding pocket, it might
additionally inhibit nAChR by competitive antagonism. Finally,
our docking results do not support a role of DEA as a partial
nAChR agonist because of, at least partially, its small size. Thus,
although DEA interacted with A-loop residues from the α-
subunit, this binding site was 15–18 Å below the C loop, which
is known to contribute with key residues to the ligand-binding
site (Corringer et al., 2000). Moreover, the docking-assays did not
show any equivalent hotspot for DEA binding at the interphase of
α-δ subunits. By contrast, lidocaine interacted with residues from
all α loops conforming the ACh-binding pocket, both at the α-γ
and α-δ interphases, which suggests a possible additional action
as a competitive antagonist.
In conclusion, we found that DEA, a small charged molecule
closely resembling the hydrophilic moiety of the lidocaine
molecule, mimics some, but not all the inhibitory actions of
the complete lidocaine molecule on nAChRs. So, DEA accounts
for the voltage-dependent blockade of nAChRs by lidocaine and
might also contribute to inhibit resting nAChRs, likely acting on
extracellular residues lying outside the channel pore.
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